232 related articles for article (PubMed ID: 27535002)
1. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.
Sinha C; Cunningham LC
Pediatr Blood Cancer; 2016 Dec; 63(12):2078-2085. PubMed ID: 27535002
[TBL] [Abstract][Full Text] [Related]
2. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
3. Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells.
Holubova M; Leba M; Gmucova H; Caputo VS; Jindra P; Lysak D
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311121
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
6. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
7. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J; Niu T
J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy for acute myeloid leukemia.
Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
[TBL] [Abstract][Full Text] [Related]
10. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
11. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients.
Siegler U; Meyer-Monard S; Jörger S; Stern M; Tichelli A; Gratwohl A; Wodnar-Filipowicz A; Kalberer CP
Cytotherapy; 2010 Oct; 12(6):750-63. PubMed ID: 20491532
[TBL] [Abstract][Full Text] [Related]
12. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Romee R; Rosario M; Berrien-Elliott MM; Wagner JA; Jewell BA; Schappe T; Leong JW; Abdel-Latif S; Schneider SE; Willey S; Neal CC; Yu L; Oh ST; Lee YS; Mulder A; Claas F; Cooper MA; Fehniger TA
Sci Transl Med; 2016 Sep; 8(357):357ra123. PubMed ID: 27655849
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells differentiated in vitro from cord blood CD34
Domogala A; Blundell M; Thrasher A; Lowdell MW; Madrigal JA; Saudemont A
Cytotherapy; 2017 Jun; 19(6):710-720. PubMed ID: 28428057
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
[TBL] [Abstract][Full Text] [Related]
15. Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
Yang L; Feng Y; Wang S; Jiang S; Tao L; Li J; Wang X
Int Immunopharmacol; 2021 Oct; 99():107965. PubMed ID: 34273636
[TBL] [Abstract][Full Text] [Related]
16. Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia.
Hussein BA; Hallner A; Wennström L; Brune M; Martner A; Hellstrand K; Bernson E; Thorén FB
Front Immunol; 2021; 12():796072. PubMed ID: 34956230
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
18. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands.
Sanchez-Correa B; Morgado S; Gayoso I; Bergua JM; Casado JG; Arcos MJ; Bengochea ML; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2011 Aug; 60(8):1195-205. PubMed ID: 21644031
[TBL] [Abstract][Full Text] [Related]
19. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A
Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.
Orleans-Lindsay JK; Barber LD; Prentice HG; Lowdell MW
Clin Exp Immunol; 2001 Dec; 126(3):403-11. PubMed ID: 11737054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]